BFM
DMRA

Boothbay Fund Management’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Boothbay Fund Management’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.86M Buy
110,441
+14,643
+15% +$376K 0.04% 493
2025
Q4 		$2.2M Buy
+95,798
New +$1.66M 0.03% 534

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $281M AUM

Boothbay Fund Management's DMRA Position: Q1 2026 in Review

Boothbay Fund Management increased its Damora Therapeutics, Inc. Ordinary Shares (DMRA) stake by 15% in Q1 2026, buying an estimated $376K and bringing the position to 110,441 shares worth $2.86M. The position accounts for 0.04% of the portfolio, ranked #493.

Boothbay Fund Management first reported a position in DMRA in Q4 2025 and has held it in 2 quarters since. 65 funds tracked by Wall St. Rank hold DMRA as of Q1 2026.

  • Boothbay Fund Management held 110,441 shares of Damora Therapeutics, Inc. Ordinary Shares worth $2.86M as of Q1 2026.
  • Boothbay Fund Management bought 14,643 Damora Therapeutics, Inc. Ordinary Shares shares in Q1 2026, an estimated $376K.
  • Damora Therapeutics, Inc. Ordinary Shares made up 0.04% of Boothbay Fund Management's portfolio in Q1 2026, its #493 holding.
  • Boothbay Fund Management first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q4 2025 and has held it in 2 quarters since.
  • 65 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.